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Illuminance and Conventional
Autofluorescence Imaging in Stargardt Macular
DystrophyRUPERT W. STRAUSS, BEATRIZ MUN˜OZ, ANAMIKA JHA, ALEXANDER HO, ARTUR V. CIDECIYAN,
MELISSA L. KASILIAN, YULIA WOLFSON, SRINIVAS SADDA, SHEILA WEST, HENDRIK P.N. SCHOLL, AND
MICHEL MICHAELIDES PURPOSE: To compare grading results between short-
wavelength reduced-illuminance and conventional auto-
fluorescence imaging in Stargardt macular dystrophy.
 DESIGN: Reliability study.
 METHODS: SETTING: Moorfields Eye Hospital, London
(United Kingdom). PATIENTS: Eighteen patients (18
eyes) with Stargardt macular dystrophy. OBSERVATION
PROCEDURES: A series of 3 fundus autofluorescence images
using 3 different acquisition parameters on a custom-
patched device were obtained: (1) 25% laser power and
total sensitivity 87; (2) 25% laser power and freely
adjusted sensitivity; and (3) 100% laser power and freely
adjusted total sensitivity (conventional). The total area of
2 hypoautofluorescent lesion types (definitely decreased
autofluorescence and poorly demarcated questionably
decreased autofluorescence) was measured. MAIN
OUTCOME MEASURES: Agreement in grading between the
3 imaging methods was assessed by kappa coefficients
(k) and intraclass correlation coefficients.
 RESULTS: The mean ± standard deviation area for im-
ages acquired with 25% laser power and freely adjusted
total sensitivity was 2.04 ± 1.87 mm2 for definitely
decreased autofluorescence (n [ 15) and 1.86 ±
2.14 mm2 for poorly demarcated questionably decreased
autofluorescence (n [ 12). The intraclass correlation
coefficient (95% confidence interval) was 0.964upplemental Material available at AJO.com.
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© 2016 THE AUTHORS. PU(0.929, 0.999) for definitely decreased autofluorescence
and 0.268 (0.000, 0.730) for poorly demarcated ques-
tionably decreased autofluorescence.
 CONCLUSIONS: Short-wavelength reduced-illuminance
andconventional fundus autofluorescence imaging showed
good concordance in assessing areas of definitely decreased
autofluorescence. However, there was significantly higher
variability between imaging modalities for assessing
areas of poorly demarcated questionably decreased
autofluorescence. (Am J Ophthalmol 2016;168:
269–278.  2016 The Authors. Published by Elsevier
Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).)
S
TARGARDTMACULARDYSTROPHY IS THEMOSTCOM-
mon form of juvenile macular degeneration.1,2 It is
an autosomal recessively inherited disorder caused
by disease-causing variants in the ABCA4 gene, encoding
a photoreceptor-specific ATP-binding cassette transporter
involved in active transport of all-trans-retinal across the
disc membranes within photoreceptor outer segments.3
Failure of this process leads to the accumulation of N-reti-
nylidene-N-retinyethanolamine (A2E), one of the major
components of lipofuscin in the retinal pigment epithe-
lium.4 High concentrations of N-retinylidene-N-retinye-
thanolamine and lipofuscin are believed to be cytotoxic,
leading to dysfunction and cell death of the retinal pigment
epithelium and photoreceptors. Clinically, one of the early
hallmarks of Stargardt macular dystrophy is retinal ‘‘flecks,’’
which represent areas of lipofuscin accumulation. Flecks
can resorb over time, and with disease progression, macular
atrophy occurs with deterioration of retinal function.5
These characteristic features of Stargardt macular dystro-
phy can be easily and noninvasively imaged by confocal
scanning laser fundus autofluorescence using signals origi-
nating from fluorophores (such as lipofuscin) within the
retina and the retinal pigment epithelium after excitation
by short-wavelength light.6 The accumulation of lipofuscin
leads to areas of increased autofluorescence, whereas areas
of atrophy are associated with decreased autofluorescence.5
Since its early descriptions,7,8 fundus autofluorescence has269BLISHED BY ELSEVIER INC.
been widely explored, and recent technological advances,
especially the introduction of confocal laser
ophthalmoscopy and frame averaging techniques, have
led to a significantly improved signal-to-noise ratio and
enhanced quality of fundus autofluorescence images.6
For these reasons, and because the U.S. Food and Drug
Administration is considering fundus autofluorescence as
a possible surrogate endpoint for clinical trials,9 fundus
autofluorescence has been chosen as the primary outcome
measure in the ‘‘Natural History of the Progression of Star-
gardt Disease: Retrospective and Prospective Studies’’
(ProgStar; ClinicalTrials.gov Identifier NCT01977846).
These multicenter studies aim to characterize the natural
course of Stargardt macular dystrophy and to validate
possible outcome measures for emerging clinical trials
including gene therapy, stem cell therapy, and pharmaco-
therapy.10
However, the appropriate fundus autofluorescence
imaging protocols remain controversial, in terms of both
limiting potential toxicity from short-wavelength light
and ensuring optimum image quality and thereby measure-
ment sensitivity to monitor disease progression. One mech-
anism of the aforementioned cytotoxicity of
N-retinylidene-N-retinyethanolamine is its mediation
through blue light–induced damage to retinal pigment
epithelial cells by photooxidative damage.11,12 The high-
intensity and short-wavelength excitation light used in
conventional fundus autofluorescence imaging could, at
least in principle, increase the rate of lipofuscin accumula-
tion and/or its toxicity.13 Cideciyan and associates were the
first to describe the concept of using short-wavelength
reduced-illuminance autofluorescence imaging in
ABCA4-associated retinopathy to reduce potential
toxicity13; however, the question remains whether image
integrity is compromised. Although short-wavelength
reduced-illuminance autofluorescence imaging results
have been reported to be both qualitatively and quantita-
tively comparable to those in the literature on conven-
tional fundus autofluorescence imaging, one described
practical shortcoming was noisier and darker images
apparent on the acquisition screen, leading to more diffi-
cult imaging.13
In the context of the ProgStar study, we acquired images
where the power of the imaging laser beam was reduced to
25% of its conventional setting. For this purpose, a special
software tool was developed and provided by Heidelberg
Engineering (Heidelberg, Germany) to all participating
sites in the ProgStar study.10
The purpose of this study is therefore to compare the
grading results of images obtained using the short-
wavelength reduced-illuminance autofluorescence imaging
method with those obtained with conventional fundus
autofluorescence imaging in the same patient cohort and
determine the correlation and areas of disagreement. This
has implications for both routine clinical care and clinical
trial endpoint design.270 AMERICAN JOURNAL OFMETHODS
THIS RELIABILITY STUDY WAS APPROVED BY THE LOCAL
Ethics Committee of Moorfields Eye Hospital, NHS Foun-
dation Trust; adhered to the provisions of the Declaration
of Helsinki; and complied with the Health Insurance Porta-
bility and Accountability Act. Ethics committee approval
for the ProgStar study was granted by the Western Institu-
tional Review Board, the local Ethics Committee of Moor-
fields Eye Hospital, NHS Foundation Trust, the
institutional review board of Johns Hopkins University
School of Medicine, and the Human Research Protection
Office of the U.S. Army Medical Research & Materiel
Command, prior to enrollment of the first patient, respec-
tively. These studies have been registered at www.
clinicaltrials.gov (Identifier NCT01977846). Written
informed consent was obtained by all participants and (if
applicable) their guardians prior to enrollment.
 SUBJECTS: Inclusion criteria were as follows:
 Age of at least 6 years
 Molecularly confirmed Stargardt macular dystrophy
with at least 2 likely disease-causing mutations in
ABCA4; if only 1 mutation was present, the patient
had to have the typical phenotype for Stargardt mac-
ular dystrophy (ie, flecks at the level of the retinal
pigment epithelium)
 Atrophic lesion of at least 300 mm in diameter; all le-
sions together must total less than 5 standard disc di-
ameters (¼ 12.00 mm2)
 Clear ocular media and adequate pupillary dilation to
permit good-quality fundus autofluorescence imaging
 Participation in the prospective ProgStar study.
Exclusion criteria were as follows:
 Other ocular disease, such as choroidal neovasculari-
zation, diabetic retinopathy, and degenerative retinal
dystrophies other than Stargardt macular dystrophy
 Intraocular surgery 90 days prior to the imaging visit
 Current or previous participation in an interven-
tional study for Stargardt macular dystrophy, such
as gene or stem cell therapy.
 STUDY DESIGN AND IMAGE ACQUISITION: Pupils were
dilated with 1% tropicamide and 2.5% phenylephrine hy-
drochloride and fundus autofluorescence images were ac-
quired using a Spectralis FA þ OCT device (Heidelberg
Engineering, Heidelberg, Germany). The device was equip-
ped with a custom-developed software tool provided by
Heidelberg Engineering to reduce laser intensity during
acquisition of fundus autofluorescence images. Using this
software tool, the laser power can be reduced to 25%,
50%, or 75% of the preset 100% laser power. Three images
with different acquisition parameters were obtained in theAUGUST 2016OPHTHALMOLOGY
study eye of each patient by 1 of 4 experienced photogra-
phers certified for the ProgStar study. All images were ac-
quired with a 30-degree field of view in the high-speed
mode centered on the anatomic fovea, not normalized,
and an automatic real-time (ART) averaging of >_15 frames.
Differences in the parameter settings were in the laser po-
wer and total sensitivity: (1) the first image was obtained
with a laser power of 25% and a fixed total sensitivity of
87 over an imaging duration ofw5 seconds; (2) the second
image was obtained with 25% laser power; however, total
sensitivity was not fixed, but adjusted by the photographer
to optimize image illumination (‘‘freely adjusted’’); (3) the
last image was obtained with laser power 100% (conven-
tional) and total sensitivity that was adjusted for an optimal
image exposure (‘‘freely adjusted’’) over an imaging dura-
tion of w30 seconds. The 25% setting corresponds to a
retinal illuminance of 2.5 3 105 scot-trolands and the
100% setting to 10 3 105 scot-trolands. These 2 settings
would be predicted to result in rhodopsin bleaches of
12% and 95%, respectively, in normal eyes. Time interval
between each capture of images was at least 5 minutes.
 IMAGE GRADING AND ANALYSIS: Deidentified images
were sent to the Doheny Imaging Reading Center, David
Geffen School of Medicine at the University of California
Los Angeles, Los Angeles, California, and graded using a
semi-automated software tool (Heidelberg Engineering
RegionFinder). The quality of the images submitted for
grading was assessed by evaluating focus and clarity (‘‘blur-
riness’’ or ‘‘fuzziness’’).
Quantitative Parameters. Three different categories of
areas of decreased autofluorescence were graded.14 The
reference points for a scale of decreased autofluorescence
were the optic nerve head and blood vessels as ‘‘100%
level of darkness’’ and the peripheral retinal background
fundus autofluorescence as ‘‘0% level of darkness.’’ The
term ‘‘definitely decreased autofluorescence’’ was defined
for areas in which the level of darkness was close to
100% (at least 90%) in reference to the optic nerve
head/blood vessels; regions with levels between 50% and
90% darkness were defined as ‘‘questionably decreased
autofluorescence’’; in these lesions, the sharpness of the
corresponding lesion border defined a lesion either as
‘‘well-demarcated questionably decreased
autofluorescence’’ or ‘‘poorly demarcated questionably
decreased autofluorescence.’’ In cases with multiple types
of lesion, the areas of all subtypes were summed,
respectively. Images were independently graded by 2
reading center–certified graders, with at least 1 grader
being a senior-level grader. Discordant initial assessments
underwent adjudication by a reading center investigator
if consensus could not be reached.
Qualitative Parameters. Qualitative parameters included
the following: (1) focus and clarity of images; (2) presenceVOL. 168 COMPARISON OF FUNDUS AUTOFLUOof increased autofluorescence at the lesion edge; (3) back-
ground uniformity (a homogeneous background was
defined as an even distribution of background autofluores-
cence; a heterogeneous background signal was defined as
widespread small foci of increased or reduced autofluores-
cence, as previously described5); and (4) presence of flecks.
 STATISTICALANALYSIS: The primary comparisons were
areas of decreased autofluorescence (definitely decreased
autofluorescence, well-demarcated questionably decreased
autofluorescence, and poorly demarcated questionably
decreased autofluorescence) in the 3 different image acqui-
sition settings. Kappa coefficients (k) were used for the
assessment of intergrader agreement in qualitative grading
(eg, the presence/absence of each type of decreased auto-
fluorescence, background uniformity, etc) in the respective
image, and kappa coefficients >0.61 were considered to be
indicative of good agreement. Intraclass correlation coeffi-
cients (ICC) with 95% confidence intervals (CI) were used
for the calculation of quantitative assessments (comparison
between different image acquisition parameters). Differ-
ences in area sizes were compared using the paired t test.
Statistical analyses were performed in SAS Statistical
Analysis Software Version 9.4 (SAS Institute, Cary, North
Carolina, USA) and R version 2.15.1 (The R Foundation
for Statistical Computing, Vienna, Austria).RESULTS
EIGHTEEN EYES OF 18 PATIENTS WERE ENROLLED IN THIS
reliability study at Moorfields Eye Hospital, London
(United Kingdom). If both eyes of a patient were eligible
and enrolled into the ProgStar study, 1 eye was randomly
chosen for the purpose of this study. Mean age (6 standard
deviation) was 38.3 (6 14.2) years (Supplemental Table 1;
Supplemental Material available at AJO.com). Figure 1
provides illustrative examples of images obtained with all
3 different parameter settings and respective grading results
of areas of definitely decreased autofluorescence and poorly
demarcated questionably decreased autofluorescence.
 PRESENCE/ABSENCE OF CATEGORIES OF DECREASED
AUTOFLUORESCENCE: Based on the grading of images
acquired with 25% laser power and 87 total sensitivity
(short-wavelength reduced-illuminance autofluorescence
imaging), 15 eyes had definitely decreased autofluores-
cence lesions and 12 eyes had poorly demarcated ques-
tionably decreased autofluorescence lesions. Only 1 eye
of 1 patient showed a lesion of well-demarcated ques-
tionably decreased autofluorescence (Table 1). Based
on the grading of images acquired with 25% laser power
and freely adjusted total sensitivity (short-wavelength
reduced-illuminance autofluorescence imaging), 15 eyes
had definitely decreased autofluorescence lesions, 12271RESCENCE ACQUISITION METHODS
FIGURE 1. Shown are 3 eyes of 3 representative patients (Left column, Patient 1; Middle column, Patient 2; Right column, Patient
3) imaged with 3 different parameter settings (Top row: 25% laser power, total sensitivity 87; Middle row: 25% laser power, freely
adjusted total sensitivity; Bottom row: 100% laser power, freely adjusted total sensitivity) and the respective grading of definitely
decreased autofluorescence and poorly demarcated questionably decreased autofluorescence as provided by the Heidelberg Region-
Finder tool. These images were contrast- and shadow-corrected by the software. Patient 1: (Top left) Total area of definitely decreased
autofluorescence (pink) was 4.24 mm2, total area of poorly demarcated questionably decreased autofluorescence (orange) was
5.22 mm2. (Middle left) Total area of definitely decreased autofluorescence (pink) was 3.92 mm2, total area of poorly demarcated
questionably decreased autofluorescence (yellow) was 2.55 mm2. (Bottom left) Total area of definitely decreased autofluorescence
(pink) was 4.20 mm2, total area of poorly demarcated questionably decreased autofluorescence (orange) was 3.91 mm2. Patient 2:
(Top middle) Total area of definitely decreased autofluorescence (pink and orange) was 4.42 mm2, total area of poorly demarcated
questionably decreased autofluorescence (yellow) was 8.03 mm2. (Center) Total area of definitely decreased autofluorescence
(pink and orange) was 3.26 mm2, total area of poorly demarcated questionably decreased autofluorescence (yellow) was
1.35 mm2. (Bottom middle) Total area of definitely decreased autofluorescence (pink and orange) was 4.15 mm2, total area of poorly
demarcated questionably decreased autofluorescence (yellow) was 8.97mm2. Patient 3: (Top right) Total area of decreased autofluor-
escence (pink and orange) was 1.39 mm2, total area of poorly demarcated questionably decreased autofluorescence (yellow) was
3.60 mm2. (Middle right) Total area of definitely decreased autofluorescence (pink, orange, and yellow) was 1.11 mm2, total area
of poorly demarcated questionably decreased autofluorescence (green) was 3.31 mm2. (Bottom right) Total area of definitely
decreased autofluorescence (pink and orange) was 1.24mm2, total area of poorly demarcated questionably decreased autofluorescence
(yellow) was 3.33 mm2.eyes had poorly demarcated questionably decreased auto-
fluorescence lesions, and no eyes had lesion(s) of well-
demarcated questionably decreased autofluorescence
(Tables 1 and 2). In contrast, with conventional fundus
autofluorescence, 14 eyes had definitely decreased auto-
fluorescence lesions and 12 eyes had poorly demarcated
questionably decreased autofluorescence lesions. One
eye had lesion(s) of well-demarcated questionably
decreased autofluorescence (Tables 1 and 2).
 AREA OF DEFINITELY DECREASED AUTOFLUORES-
CENCE: The mean 6 standard deviation (SD) for the area
of definitely decreased autofluorescence was 2.04 6
1.87 mm2 in images obtained with 25% laser power/total272 AMERICAN JOURNAL OFsensitivity 87, 1.88 6 1.79 mm2 in images obtained with
25% laser power/freely adjusted total sensitivity, and 2.00
6 1.86 mm2 in images obtained with conventional fundus
autofluorescence. Figure 2 (Left) illustrates the measure-
ments of areas of definitely decreased autofluorescence using
the 3 different acquisition settings. These measurements of
definitely decreased autofluorescence derived from all 3
acquisition settings were highly correlated with each other
(Table 3); the ICC (95% CI) was 0.964 (0.929, 0.999)
when comparing images acquired at 25% laser power/freely
adjusted total sensitivity and conventional fundus autofluor-
escence. There was no statistically significant difference in
determination of area size between the 3 acquisition param-
eter settings (Table 3); moreover, when comparing imageAUGUST 2016OPHTHALMOLOGY
TABLE 1.Grading of Absolute Presence or Absence of 3 Different Lesion Categories of Decreased Autofluorescence AcquiredWith 3
Different Image Acquisition Settings
Acquisition Parameters Number of Eyes With Definitely Decreased Autofluorescence
Laser power 25%, 87 total sensitivity
Absent 3
Present 15
Laser power 25%, freely adjusted total sensitivity
Absent 3
Present 15
Laser power 100%, freely adjusted total sensitivity
Absent 4
Present 14
Number of Eyes With Well-Demarcated Questionably Decreased Autofluorescence
Laser power 25%, 87 total sensitivity
Absent 17
Present 1
Laser power 25%, freely adjusted total sensitivity
Absent 17
Present 1
Laser power 100%, freely adjusted total sensitivity
Absent 17
Present 1
Number of Eyes With Poorly-Demarcated Questionably Decreased Autofluorescence
Laser power 25%, 87 total sensitivity
Absent 6
Present 12
Laser power 25%, freely adjusted total sensitivity
Absent 6
Present 12
Laser power 100%, freely adjusted total sensitivity
Absent 6
Present 12acquisition settings with freely adjusted total sensitivity
(laser power 25% and laser power 100%), the mean 6 SD
difference in area between the 2 modalities was 0.124
(0.473) mm2 (P ¼ .28). In a previous study for measuring
areas of definitely decreased autofluorescence, ICC for inter-
grader agreement was 0.993 (0.986, 0.996) using the semi-
automated software tool (Heidelberg RegionFinder) and
the ICC for intragrader agreement was 0.981 (0.963,
0.990) using the same semi-automated software tool (Hei-
delberg RegionFinder).14
 AREA OF POORLY DEMARCATED QUESTIONABLY
DECREASED AUTOFLUORESCENCE: Figure 2 (Right) il-
lustrates the measurements of areas of poorly demarcated
questionably decreased autofluorescence using the 3
different acquisition settings. The mean 6 standard
deviation for areas of poorly demarcated questionably
decreased autofluorescence as determined with
the 3 different acquisition parameters was more variable
(n ¼ 12 eyes). The greatest area was 1.86 6 2.14 mm2VOL. 168 COMPARISON OF FUNDUS AUTOFLUOin images obtained with 25% laser power/total
sensitivity 87. The lowest was 1.276 1.40 mm2 in images
obtained with 25% laser power/freely adjusted total sensi-
tivity. In images obtained with conventional fundus
autofluorescence, the area of poorly demarcated ques-
tionably decreased autofluorescence was 1.75 6
2.33 mm2; the differences were not statistically signifi-
cant (Table 4).
There was variation in the ICCs of measured lesion
areas between these different image acquisition parame-
ters and also for the detected differences in area sizes
(Table 4). The ICC was 0.268 (0.000, 0.730) for poorly
demarcated questionably decreased autofluorescence for
the comparison between images obtained at 25% laser
power/freely adjusted total sensitivity and conventional
fundus autofluorescence. The mean 6 SD difference in
area between the 2 modalities was 0.479 6 2.92 mm2
(P ¼ .39). In a previous study for measuring areas of
poorly demarcated questionably decreased autofluores-
cence, ICC for intergrader agreement was 0.715273RESCENCE ACQUISITION METHODS
TABLE 2. Distribution of Grading and Kappa Values (95%Confidence Limits) for Grading of Presence or Absence of 3 Different Lesion
Categories of Decreased Autofluorescence Acquired With 3 Different Image Acquisition Settings (Where Applicable)
Acquisition Parameters
Presence/Absence of Areas of Definitely Decreased Autofluorescence
Laser power 25%, freely adjusted total sensitivity Laser power 100%, freely adjusted total sensitivity
Absent Present Absent Present
Laser power 25%, 87 total
sensitivity
Absent 2 1 3 0
Present 1 14 1 14
Kappa (95% confidence limits) ¼ 0.60 (0.10–1.00) Kappa (95% confidence limits) ¼ 0.82 (0.49–1.00)
Absent Present
Laser power 25%, freely
adjusted total sensitivity
—————————————————
Absent 3 0
Present 1 14
Kappa (95% confidence limits) ¼ 0.82 (0.49–1.00)
Acquisition parameters
Presence/Absence of Areas of Well-Demarcated Questionably Decreased Autofluorescence
Laser power 25%, freely adjusted total sensitivity Laser power 100%, freely adjusted total sensitivity
Absent Present Absent Present
Laser power 25%, 87
total sensitivity
Absent 17 0 17 0
Present 1 0 0 1
Kappa n/aa Kappa ¼ 1.0
Absent Present
Laser power 25%, freely
adjusted total
sensitivity
—————————————————
Absent 16 1
Present 0 0
Kappa n/aa
Acquisition parameters
Presence/Absence of Areas of Poorly Demarcated Questionably Decreased Autofluorescence
Laser power 25%, freely adjusted total sensitivity Laser power 100%, freely adjusted total sensitivity
Absent Present Absent Present
Laser power 25%, 87 total
sensitivity
Absent 5 1 5 1
Present 1 11 1 11
Kappa (95% confidence limits) ¼ 0.75 (0.42–1.00) Kappa (95% confidence limits) ¼ 0.75 (0.42–1.00)
Absent Present
Laser power 25%, freely
adjusted total sensitivity
—————————————————
Absent 6 0
Present 0 12
Kappa ¼ 1.0
aKappa was not calculated when row/column marginal was zero.
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FIGURE 2. Measurements of areas of definitely decreased autofluorescence (Left) and poorly demarcated questionably decreased
autofluorescence (Right) in the 18 eyes of 18 participants enrolled into this study. Images were acquired with 3 different parameter
settings: 2 images were obtained with short-wavelength reduced-illuminance autofluorescence imaging using 25% laser power/total
sensitivity 87 and 25% laser power/freely adjusted total sensitivity, and 1 image was obtained with conventional fundus autofluor-
escence imaging (100% laser power and freely adjusted total sensitivity). AVG[ average and standard deviation (bars) of area mea-
surements; areas of absent decreased autofluorescence (zeros) were included, respectively.
TABLE 3. Measures of Agreement in Areas of Definitely Decreased Autofluorescence Among Images Acquired With 3 Different
Acquisition Parameters
Acquisition Parameters Statistic
Acquisition Parameters
25% Laser Power/Total Sensitivity
Freely Adjusted
100% Laser Power/Total Sensitivity
Freely Adjusted
25% laser power,
total sensitivity 87
Difference in area of DDAF,
mean(SD)
0.16 (0.51) mm2 (P ¼ .20)a 0.036 (0.175) mm2, (P ¼ .40)a
% Outside limits of
agreement
2/18 (11.1%) 1/18 (5.5%)
Intraclass correlation
coefficient (95% CI)
0.957 (0.915–0.999) 0.995 (0.991–1.00)
25% laser power,
total sensitivity freely adjusted
Difference in area of DDAF,
mean(SD)
__________________ 0.124 (0.473) mm2, (P ¼ .28)a
% Outside limits of
agreement
__________________ 1/18 (5.5%)
Intraclass correlation
coefficient (95% CI)
__________________ 0.964 (0.929–0.999)
CI ¼ confidence interval; DDAF ¼ definitely decreased autofluorescence.
aPaired t test.(0.415, 0.875) using the semi-automated software tool
(Heidelberg RegionFinder) and the ICC for intragrader
agreement was 0.875 (0.715, 0.948) using the same
semi-automated software tool (Heidelberg Region-
Finder).14VOL. 168 COMPARISON OF FUNDUS AUTOFLUO QUALITATIVE MEASURES: Focus and clarity were deter-
mined as adequate by the graders in all 18 eyes for images
obtained with freely adjusted total sensitivity and laser po-
wer of 25% and 100%, respectively. The image quality for 3
eyes was judged as fair for images acquired with 25% laser275RESCENCE ACQUISITION METHODS
TABLE 4.Measures of Agreement in Areas of Poorly DemarcatedQuestionably Decreased Autofluorescence Among Images Acquired
With 3 Different Acquisition Parameters
Acquisition Parameters Statistic
Acquisition Parameters
25% Laser Power/Total Sensitivity
Freely Adjusted
100% Laser Power/Total Sensitivity
Freely Adjusted
25% laser power,
total sensitivity 87
Difference in area of PD-QDAF,
mean(SD)
0.59 (1.74) mm2, (P ¼ .18)a 0.11 (0.133) mm2, (P ¼ .72)a
% Outside limits of agreement 4/18 (22.2%) 2/18 (11.1%)
Intraclass correlation coefficient (95% CI) 0.494 (0.117–0.870) 0.821 (0.659–0.983)
25% laser power,
total sensitivity freely adjusted
Difference in area of PD-QDAF, mean(SD) __________________ 0.479 (2.92) mm2, (P ¼ .39)a
% Outside limits of agreement __________________ 2/18 (11.1%)
Intraclass correlation coefficient (95% CI) __________________ 0.268 (0.000–0.730)
CI ¼ confidence interval; PD-QDAF ¼ poorly-demarcated questionably decreased autofluorescence.
aPaired t test.power/total sensitivity 87 (Supplemental Table 2; Supple-
mental Material available at AJO.com). Comparing the
images obtained with the 3 different acquisition parame-
ters, k was 1.00 for the presence of flecks and for grading
of a homogeneous or heterogeneous background signal,
respectively. However, there were differences in grading
increased autofluorescence at lesion edges between the im-
ages obtained with 25% laser power/total sensitivity 87,
25% laser power/free adjusted total sensitivity, and conven-
tional fundus autofluorescence (Supplemental Table 2).DISCUSSION
SEVERAL FACTORS WERE CONSIDERED DURING THE DESIGN
of the ProgStar study with regard to the use of fundus auto-
fluorescence imaging.10 First, the research team weighed
the risks of the elevated concentration of N-retinylidene-
N-retinyethanolamine/lipofuscin found in Stargardt macu-
lar dystrophy, which is believed to be a contributor to cell
death, and the possibility that the application of high-
intensity short-wavelength blue light during fundus auto-
fluorescence imaging could accentuate this toxicity.11,13
This becomes particularly relevant in a natural history
study, as serial imaging will be performed at regular
intervals, and the imaging procedure itself may
potentially contribute to N-retinylidene-N-
retinyethanolamine accumulation and/or
photooxidation.13 Second, although all ophthalmic imag-
ing instruments are designed to operate well below safe
retinal light damage thresholds, it must be noted that dam-
age thresholds are derived from data using healthy retinas,
whereas diseased retinas may have lower light damage
thresholds.13,15 Thus, there is a potential safety concern
with the use of high laser powers.276 AMERICAN JOURNAL OFAnother potential benefit of the short-wavelength
reduced-illuminance autofluorescence imaging approach
is that it is a more comfortable imaging experience
compared to conventional fundus autofluorescence imag-
ing. The authors have anecdotal evidence of patients
within the ProgStar study who questioned their continued
participation owing to potential phototoxicity from fundus
autofluorescence light exposure but were reassured by the
reduced light intensities used in the short-wavelength
reduced-illuminance autofluorescence imaging approach.
However, there was concern that by using less laser po-
wer or differences in sensitivity compared to conventional
fundus autofluorescence, we would sacrifice image clarity
and/or reduce accurate detection of all types of lesion and
thereby compromise accurate measurement of progression,
including assessment of total lesion area(s).
Owing to these aforementioned uncertainties, we
conducted this study to directly compare 3 fundus auto-
fluorescence imaging protocols (2 short-wavelength
reduced-illuminance autofluorescence imaging parameters
and conventional fundus autofluorescence) in a cohort of
18 patients with Stargardt macular dystrophy. In this
cross-sectional study, we found no significant difference
in the determination of the presence or absence of defi-
nitely decreased autofluorescence, or in area of definitely
decreased autofluorescence, among the 3 autofluorescence
image acquisition techniques. This finding is reassuring
that reducing the illumination intensity will not compro-
mise accurate detection and measurement of definitely
decreased autofluorescence.
There was also good agreement in grading the presence
and absence of poorly demarcated questionably decreased
autofluorescence across all 3 image acquisition techniques;
however, there was a difference in the area of poorly demar-
cated questionably decreased autofluorescence measured
from images acquired by the different techniques. The
largest mean area was observed using 25% laser powerAUGUST 2016OPHTHALMOLOGY
and 87 total sensitivity, which might be explained by the
lower contrast that is typically observed in these images
(Figure 1). However, such variability in grading lesion areas
in poorly demarcated questionably decreased autofluores-
cence has also been observed in a previous pilot study
published by Kuehlewein and associates, which evaluated
the grading protocols for ProgStar14: fundus autofluores-
cence images obtained with 100% laser power and freely
set total sensitivity (conventional fundus autofluorescence)
were graded twice by different graders, and the main diffi-
culty was the determination of borders in lesions with a
black level close to the lowest threshold to be considered
poorly demarcated questionably decreased autofluores-
cence. The ICC for intergrader agreement was 0.715
(0.415, 0.875) using the semi-automated software tool
(Heidelberg RegionFinder) and the ICC for intragrader
agreement was 0.875 (0.715, 0.948). In our study herein,
the ICCs varied from 0.268 (0.000, 0.730), in the compar-
ison between 25% laser power/freely adjusted total sensi-
tivity and conventional fundus autofluorescence, to 0.821
(0.659, 0.983) when comparing 25% laser power/87 total
sensitivity to conventional fundus autofluorescence. This
finding seems counterintuitive, as we expected that the
fixed setting of 25% laser power and total sensitivity of
87 would lead to lower ICCs in comparison with the other
settings that allowed the photographer to adjust the total
sensitivity. The increase in laser power appears to almost
always necessitate a reduction in total sensitivity in order
not to overexpose the resulting image, and therefore, im-
ages with higher laser power/lower total sensitivity are
similar to those acquired with lower laser power/higher to-
tal sensitivity (Figure 1). We therefore believe that the
variation and differences, both for ICCs and determined
lesion areas in poorly demarcated questionably decreased
autofluorescence cases, are due to the difficulty in delin-
eating a lesion with poorly demarcated borders reliably
and reproducibly, rather than in use of the short-
wavelength reduced-illuminance autofluorescence imaging
method per se.
Also, the concordance of qualitative measures such as
the presence/absence of flecks and background heterogene-
ity was excellent, while differences in the grading of pres-
ence of hyperfluorescence at the lesion edge might be
attributable to the differences in contrast.
The finding that short-wavelength reduced-illuminance
autofluorescence imaging was comparable to conventional
imaging for definitely decreased autofluorescence in our
cross-sectional study may also have implications for its
adoption in routine patient care. However, it will be impor-
tant to also undertake a longitudinal study to determine
how the imaging methods compare over time in assessing
progression—especially in areas of more subtle patterns ofVOL. 168 COMPARISON OF FUNDUS AUTOFLUOaltered FAF—in terms of its use in monitoring patients in
clinic over time, but moreover for the purposes of clinical
trial endpoint design.
Our study has some limitations. First, the number of eyes
was small and thus, we could not assess differences between
fundus autofluorescence acquisition methods for less com-
mon Stargardt fundus autofluorescence patterns, such as
well-demarcated questionably decreased autofluorescence.
Second, though the same photographer acquired the im-
ages with all 3 methods, we could not necessarily ensure
that differences between the images were due to only the
acquisition method, and not due to variability in the pho-
tographer’s technique. Third, despite a break of at least
5 minutes between single image acquisitions, and also start-
ing with the minimum laser power (25% laser power), there
might have been a degree of bleaching effect that theoret-
ically could affect the decreased autofluorescence categori-
zation. It would be helpful if the grading software tool
(Heidelberg RegionFinder) provided actual gray levels of
the lesions to the graders.
A quantitative autofluorescence imaging and analysis
method does exist16; however, bleaching of photoreceptors
is a requirement for accurate analysis, and such an approach
counteracts the underlying conceptual benefits of short-
wavelength reduced-illuminance autofluorescence
imaging.
Strengths of our study include the image acquisition
by experienced, certified photographers at a single cen-
ter using the same device, the fact that all image modal-
ities for a given subject were obtained by the same
photographer, and the application of standardized
grading procedures by certified, experienced reading
center graders.
In summary, short-wavelength reduced-illuminance
autofluorescence imaging is a well-tolerated method to ac-
quire fundus autofluorescence images, both clinically and,
particularly, in the context of natural history studies where
regular serial imaging is being undertaken. The acquisition
of an image of good contrast by the photographer is of para-
mount importance for reliable grading results; our study
provides valuable data that this can also be achieved by
the use of short-wavelength reduced-illuminance auto-
fluorescence imaging with freely adjusted total sensitivity.
The ProgStar studies will shed further light into which
types of decreased autofluorescence may serve as potential
and reliable outcomemeasures. It may be speculated that in
patients exhibiting lesions where fundus autofluorescence
is relatively challenging from a measurement perspective
(eg, poorly demarcated questionably decreased autofluores-
cence), other imaging modalities may be better suited to
track disease progression, including spectral-domain opti-
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